Eli Lilly and Co. received approval from the FDA for Cymbalta (duloxetine HCl) for the management of chronic musculoskeletal pain. This indication was established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. This is Cymbalta’s fifth indication approved by the FDA. Cymbalta, a non-narcotic pain reliever, has been shown to significantly reduce chronic low back pain and chronic pain due to osteoarthritis. It is believed that Cymbalta helps lessen pain...